Navigation Links
Vermillion Reports Results for Third Quarter 2011

AUSTIN, Texas, Nov. 9, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, reported financial results for the third quarter ended September 30, 2011.

Q3 2011 Highlights

  • Performed an estimated 4,108 OVA1® tests during the third quarter, up 5% from the previous quarter.
  • In October, released positive top-line data from intended use clinical study of the company's peripheral artery disease (PAD) blood test. Developed a biomarker panel which identifies more than 80% of PAD patients who are missed by the Framingham Risk Score.
  • In November, strengthened patent portfolio with notice of allowance received for key PAD biomarker patent, as well as issued a patent for lung cancer biomarker.
  • Enhanced management team with addition of Donald Munroe, Ph.D. as chief scientific officer and vice president of research and development.
  • Presented data at the European Society of Gynecologic Oncology meeting in Milan, highlighting the improvement in sensitivity when using imaging in conjunction with OVA1 to evaluate adnexal masses for disease.
  • Entered into an asset purchase agreement with Correlogic Systems, Inc., whereby Vermillion has agreed to pay $435,000 in cash for substantially all of Correlogic's assets in connection with its ovarian cancer diagnostics business, which include certain diagnostic samples, software and IP.  Correlogic is in Chapter 11 proceedings in the United States Bankruptcy Court for the District of Maryland and the transaction is subject to Court approval.

  • Q3 2011 Financial HighlightsRevenue for the third quarter of 2011 included $206,000 from sales of OVA1, as compared to $114,000 in the same year-ago quarter. Total revenue for the third quarter of 2011 was $320,000 versus $413,000 in the same year-ago quarter. License revenue for the third quarter of 2011 totaled $114,000, as compared to $299,000 in the same year-ago quarter related to the company's past achievement of certain milestones under the Strategic Alliance Agreement with Quest Diagnostics.

    Total operating expenses increased in the third quarter of 2011 to $4.8 million from $4.0 million in the same period a year ago. The increase was due primarily to higher clinical trial and collaboration costs for the ongoing development of the company's ovarian cancer program and VASCLIR as well as an increase in legal fees associated with our Molecular Analytical Systems, Inc. litigation. Operating expenses in the third quarter of 2011 included $0.4 million in non-cash stock-based compensation, as compared to $1.2 million in the same year-ago quarter.

    Net loss for the third quarter was $4.7 million or $(0.31) per share, as compared to $2.7 million or $(0.26) per share in the same year-ago quarter. Net loss in the year-ago quarter included $1.0 million in other income resulting from the fair value revaluation of common stock warrants.

    Weighted average shares outstanding were 14.8 million in the third quarter of 2011, as compared to 10.5 million weighted average shares outstanding in the same period in 2010.

    As of September 30, 2011, the company's cash and cash equivalents totaled $27.2 million. The company used $4.3 million in cash from operations during the third quarter and paid the $5 million principal amount of convertible notes which became due in September. Cash utilization from operations during the fourth quarter is expected to be $4-$5 million.

    Management Commentary"Our third quarter results demonstrated on-going progress on several fronts," said Gail Page, the company's president and CEO. "We grew OVA1 sales and highlighted its benefit when used in conjunction with imaging as an aid for physicians in the assessment of adnexal masses. Strategically, we are pleased to announce the agreement to purchase the ovarian cancer assets of Correlogic Systems. This acquisition allows us to gain access to their samples, IP and software, all of which could be additive to our ovarian program. Additionally, we save sample collection time and potentially gain further IP protection.

    "We also advanced our pipeline this quarter with positive top-line results in our PAD intended use clinical study. This data was subsequently used to select a biomarker combination that identifies 80% of PAD patients missed by the conventional Framingham Risk Score. The availability of a simple blood test to reclassify patients missed by conventional risk assessment could greatly aid in the detection and management of this insidious disease.

    "In the fourth quarter of 2011, we expect 4,000 to 4,300 OVA1 tests to be performed. This takes into consideration the impact of holidays, competition and limited coverage by the larger payers combined with the impact of direct patient bills."

    Conference Call DetailsThe company will conduct a conference call to discuss its third quarter results later today at 8:30 a.m. Eastern time (Wednesday, November 9).

    Interested parties may listen to the call by dialing (800) 686-5266 from the United States and Canada or +1 (303) 223-2680 internationally. The conference ID is 21542209.

    A live webcast and replay will also be available via the Investor Relations section of the company's website at

    A telephone replay of the call will be available beginning approximately two hours after the call through November 23, 2011, and may be accessed by dialing (800) 633-8284 from the United States and Canada or +1 (402) 977-9140 internationally. The replay passcode is 21542209.  

    About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found at

    Forward-Looking StatementCertain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that patients will not be able to receive reimbursement for Vermillion's tests from third party payors such as private insurance companies and government insurance plans; (5) uncertainty whether Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or more volatile; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

    This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at, Inc.Consolidated Balance Sheets(Amounts in Thousands, Except Share and Par Value Amounts)(Unaudited)September 30,December 31,20112010AssetsCurrent assets:Cash and cash equivalents

    22,914Accounts receivable

    114136Prepaid expenses and other current assets

    455779Total current assets

    27,79723,829Property and equipment, net

    237194Other assets

    1212Total assets

    24,035Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable

    998Accrued liabilities

    3,2233,056Convertible senior notes

    -5,000Deferred revenue

    1,0011,049Total current liabilities

    6,38610,103Long-term debt owed to related party

    7,0007,000Warrant liability

    -378Deferred revenue

    1,3811,679Other liabilities

    104259Total liabilities

    14,87119,419Commitments and contingencies Stockholders’ equity:Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and

    --outstanding at September 30, 2011 and December 31, 2010Common stock, $0.001 par value, 150,000,000 shares authorized at September 30, 2011and December 31, 2010; 14,848,301 and 10,657,564 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively

    1511Additional paid-in capital

    326,476303,270Accumulated deficit

    (313,164)(298,509)Accumulated other comprehensive loss

    (152)(156)Total stockholders’ equity

    13,1754,616Total liabilities and stockholders’ equity

    24,035Vermillion, Inc.Consolidated Statements of Operations(Amounts in Thousands, Except Share and Per Share Amounts)(Unaudited)Three Months Ended September 30, Nine Months Ended September 30, 2011201020112010Revenue:Product revenue

    59License revenue

    114299341671Total revenue

    3204131,055830Cost of revenue:Product

    261310525Total cost of revenue

    261310525Gross profit

    294400950805Operating expenses:Research and development(1)

    1,3701,1114,2192,797Sales and marketing(2)

    1,4991,0254,3201,751General and administrative(3)

    1,9521,8646,9826,604Total operating expenses

    4,8214,00015,52111,152Loss from operations

    (4,527)(3,600)(14,571)(10,347)Interest income

    18125525Interest expense

    (100)(117)(330)(375)Change in fair value and gain from exercise of warrants, net

    329803744,427Debt conversion costs

    ---(141)Reorganization items

    (42)(44)(74)(1,641)Reorganization items - related party incentive plan

    ---(6,932)Other income (expense), net

    (32)33(109)(36)Loss before income taxes

    (4,651)(2,736)(14,655)(15,020)Income tax expense

    ----Net loss

    (15,020)Net loss per share - basic and diluted

    (1.45)Weighted average common shares used to computebasic and diluted net loss per common share

    14,820,69410,495,32414,041,54910,345,995Non-cash stock-based compensation expense included in operating expenses:(1)  Research and development

    788(2)  Sales and marketing

    402612251(3)  General and administrative

    2119292,2642,547Investor Relations Contact:
    Liolios Group
    Ron Both
    Tel 949-574-3860
    Email Contact


    SOURCE Vermillion, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Vermillion to Present at Stephens Fall Investment Conference on November 16, 2011
    2. Vermillion Engages Liolios Group to Lead Investor Relations Program
    3. Vermillion Enhances Management Team With A Key Addition
    4. Vermillion Appoints Distribution Partner for OVA1® in Israel and the Palestine Territories
    5. Vermillion Reports Financial Results for the First Quarter 2011
    6. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
    7. Vermillion Attends 42nd Annual Meeting of the Society of Gynecologic Oncologists
    8. Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA
    9. Vermillion Announces $21.8 Million Public Offering
    10. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
    11. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
    Post Your Comments:
    (Date:11/26/2015)... November 26, 2015 3D bioprinting market ... according to a new report by Grand View Research Inc. ... (CKD) which demands kidney transplantation is expected to boost the ... substitute for organ transplantation. --> 3D bioprinting market ... according to a new report by Grand View Research Inc. ...
    (Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
    (Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
    Breaking Medicine Technology:
    (Date:11/26/2015)... Karnataka (PRWEB) , ... November ... ... innovative online platform for mental health and wellness consultation, has collaborated with ... to holistically address their reader’s queries on topics on mental and emotional ...
    (Date:11/25/2015)... ... November 25, 2015 , ... As part of a global ... attracts volunteers together who want to combine talents and resources to help create ... the process. The non-profit launched its first major fundraiser on November 6, 2015 ...
    (Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
    (Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
    (Date:11/25/2015)... ... November 25, 2015 , ... According to an article published ... and more widely heralded as a breakthrough for performing hernia repairs. The article explains ... laparoscopic surgery is that it can greatly reduce the pain that a patient might ...
    Breaking Medicine News(10 mins):